Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype

Table 2 Treatment Response According to Subtypes (n = 105 patients with measurable diseases)

	Total (n = 105)	HR (n = 68)	HER2 (n = 14)	TN (n = 23)	p
Median cycles	6.0 (1-12)	5.9 (1-12)	4.8 (1-9)	5.6 (1-9)	0.454
Response
CR	2	2	0	0
PR	55	36	6	13
SD	25	19	3	4
PD	20	11	4	5
Not evaluable	2	0	1	1
Overall response rate	57 (54.3%)	38 (55.9%)	6 (42.9%)	13 (56.5%)	0.542

CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease

ISSN: 1471-2407